Nuformix (LON:NFX) Announces Earnings Results

Nuformix (LON:NFX) released its earnings results on Thursday. The company reported GBX (0.02) EPS for the quarter, Digital Look Earnings reports.

Nuformix Price Performance

LON:NFX opened at GBX 0.17 on Thursday. The company has a market cap of £4.44 million, a P/E ratio of -4.33 and a beta of 1.55. Nuformix has a twelve month low of GBX 0.01 and a twelve month high of GBX 0.56. The business has a 50 day moving average price of GBX 0.18 and a two-hundred day moving average price of GBX 0.23.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.